Sunitinib induced pyoderma gangrenosum-like ulcerations

Area of Science:

• Dermatology
• Oncology
• Pharmacology

Background:

• Pyoderma gangrenosum is a rare, non-infectious neutrophilic skin disease often linked to systemic conditions.
• Diagnosis relies on clinical presentation due to non-specific histopathological and laboratory findings.
• Sunitinib is a multi-kinase inhibitor used to treat hepatocellular carcinoma by targeting tumor proliferation and angiogenesis.

Observation:

• A 69-year-old man developed progressive pyoderma gangrenosum-like ulcerations while undergoing sunitinib therapy for hepatocellular carcinoma.
• Standard ulcer treatments were ineffective in resolving the lesions.
• Discontinuation of sunitinib therapy resulted in significant improvement of the ulcerations.

Findings:

• Pyoderma gangrenosum-like ulcers can be a serious adverse effect of sunitinib treatment.
• The study highlights a potential causal relationship between sunitinib and the development of these ulcers.
• This case suggests that sunitinib's mechanism of action may contribute to its dermatological side effects.

Implications:

• Oncologists and dermatologists should consider sunitinib-induced pyoderma gangrenosum-like ulcers in patients presenting with similar symptoms.
• Early recognition and cessation of sunitinib may be crucial for managing these severe skin reactions.
• Further research is warranted to elucidate the precise mechanisms underlying sunitinib-associated cutaneous toxicity.